EICHOR
● Active Not Recruiting
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
Condition: Lung Non-Small Cell Carcinoma · Stage II Lung Cancer AJCC v8 · Stage IIIA Lung Cancer AJCC v8 · Sponsor: National Cancer Institute (NCI)
About this study
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (193)
| NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro, Arkansas, United States | — |
| Tower Cancer Research Foundation | Beverly Hills, California, United States | — |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | — |
| Cedars-Sinai Cancer - Tarzana | Tarzana, California, United States | — |
| Torrance Memorial Physician Network - Cancer Care | Torrance, California, United States | — |
| Hartford Hospital | Hartford, Connecticut, United States | — |
| Midstate Medical Center | Meriden, Connecticut, United States | — |
| The Hospital of Central Connecticut | New Britain, Connecticut, United States | — |
| Beebe South Coastal Health Campus | Millville, Delaware, United States | — |
| Helen F Graham Cancer Center | Newark, Delaware, United States | — |
| Medical Oncology Hematology Consultants PA | Newark, Delaware, United States | — |
| Beebe Health Campus | Rehoboth Beach, Delaware, United States | — |
+ 181 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06732401